Understanding and Predicting Loss to Follow-up from Multi-Drug Resistant Tuberculosis Treatment in the Setting of High-HIV Burden
Understanding and Predicting Loss to Follow-up from Multi-Drug Resistant Tuberculosis Treatment in the Setting of High-HIV Burden
批准号:
10676317
负责人:
Katherine C McNabb
金额:
$5.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2025-10-31
关键词:
AddressAgeAlcohol consumptionAntibiotic ResistanceAntitubercular AgentsAttentionCaringCause of DeathCessation of lifeCharacteristicsClinicalCluster randomized trialComplexCountryDataData AnalysesDevelopmentDirectly Observed TherapyEarly identificationEducational StatusEmployment StatusEventHIVHIV/TBHealth PersonnelHospitalsIndividualInjectionsInterruptionInterventionKnowledgeLinkLiteratureMachine LearningMentorshipMethodsModelingMultidrug-Resistant TuberculosisOralOutcomeParentsPatient riskPatient-Focused OutcomesPatientsPharmaceutical PreparationsProviderRecommendationRegimenResearchResistanceResource-limited settingResourcesRetrospective cohortRetrospective cohort studyRifampinRiskRisk FactorsServicesSeveritiesSouth AfricaTrainingTreatment FailureTreatment ProtocolsTreatment outcomeTuberculosisValidationWorld Health Organizationarmclinical careclinical predictive modelco-infectioncostdata cleaningdesignevidence baseexperiencefollow-uphigh riskhousing instabilityimprovedimproved outcomeindividualized medicineisoniazidlow and middle-income countriesmalemathematical modelmodel buildingmortality riskmultidisciplinarymultiple drug usepatient engagementpoint of carepredictive modelingprogramsrural residencesexsubstance usesuccesstherapy adverse effecttooltransmission processtreatment adherencetreatment risktrial enrollmenttuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Globally, Tuberculosis (TB) is one of the leading infectious causes of death and a particular concern in countries
with a high HIV burden. With only 57% of cases being successfully treated, multi-drug resistant-TB (MDR-TB)
has become a substantial barrier to TB control. High rates of loss to follow up (LTFU) (i.e., missing two or more
consecutive months of treatment) are a major contributor to the low MDR-TB treatment success rates. LTFU
may lead to additional antibiotic resistance, MDR-TB treatment failure, and death. The World Health Organization
recommends that patients at-risk for LTFU be given priority attention, but there is currently no evidence-based
way to identify these patients. In order to address this gap, the proposed study will develop a prediction model
for LTFU from MDR-TB treatment based on characteristics present at treatment initiation. If accurate, this model
will identify the patients who are at high-risk for LTFU and who will draw the greatest benefit from interventions
that promote care engagement and retention. Although the reasons for LTFU are complex, past research has
yielded a number of potential predictors that will inform the proposed prediction model, including male sex, age,
housing instability, alcohol use, substance use, employment status, education level, rural residence, and prior
episode(s) of TB. In addition to factors present at treatment initiation, the relationship between LTFU and factors
that change throughout treatment, including adverse treatment events and treatment regimen, will be examined
to develop a broader understanding of MDR-TB care engagement. The proposed study will be nested within the
control arm of a cluster-randomized trial of MDR-TB patients in South Africa (R01 AI104488). The specific aims
of the proposed study, titled “Understanding and Predicting Loss to Follow-up from MDR-TB Treatment in the
Setting of High-HIV Burden”, are to conduct a nested, retrospective cohort study among patients who were LTFU
or successfully completed MDR-TB treatment (i.e., cured or completed treatment) to: (1a) develop a prediction
model for LTFU from MDR-TB care based on the patient characteristics available at treatment initiation utilizing
LASSO regression and k-fold cross-validation; (1b) adapt the prediction model developed in Aim 1a into a tool
that can be used by providers at the point of care to estimate a patient’s risk for LTFU; (1c) determine if type of
treatment regimen is a risk factor for LTFU and if it improves the fit of the prediction model developed in Aim 1a;
and (2) examine the relationship between LTFU and the timing and burden of adverse treatment effects. This
study will be the first to take a predictive modeling approach to guide MDR-TB providers in identifying patients
at high-risk for LTFU and prioritizing their receipt of support services in order to ultimately improve MDR-TB
treatment outcomes in resource-limited settings. Through the proposed study and training plan, the applicant will
gain experience analyzing large, complex longitudinal data and applying machine learning to optimize patient
engagement and clinical care.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1371/journal.pgph.0000706
发表时间:
2023
期刊:
PLOS global public health
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1136/bmjopen-2021-054833
发表时间:
2022-03-28
期刊:
BMJ open
影响因子:
2.9
作者:
[Nguyen Y, McNabb KC, Farley JE, Warren N]
通讯作者:
Warren N
DOI:
10.1097/jnc.0000000000000365
发表时间:
2022-11-01
期刊:
JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
影响因子:
2
作者:
[Kwong, Jeffrey, McNabb, Katherine C., Voss, Joachim G., Bergman, Alanna, McGee, Kara, Farley, Jason]
通讯作者:
Farley, Jason
Combating Stigma in the Era of Monkeypox-Is History Repeating Itself?
在蒙基托克斯的历史时代重复自己的污名吗?
DOI:
10.1097/jnc.0000000000000367
发表时间:
2022-11-01
期刊:
JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
影响因子:
2
作者:
[Bergman, Alanna, McGee, Kara, Farley, Jason, Kwong, Jeffrey, McNabb, Katherine, Voss, Joachim]
通讯作者:
Voss, Joachim
DOI:
10.1186/s12889-023-17033-4
发表时间:
2023-10-31
期刊:
BMC public health
影响因子:
4.5
作者:
[]
通讯作者:
Understanding and Predicting Loss to Follow-up from Multi-Drug Resistant Tuberculosis Treatment in the Setting of High-HIV Burden
-
批准号:10326602
-
项目类别:
-
资助金额:$5.1万
-
财政年份:2021
-
负责人:Katherine C McNabb
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: